“CD47 antigen inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 28+ companies and 28+ pipeline drugs in CD47 antigen inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
• Global coverage
CD47 antigen inhibitors Understanding
CD47 antigen inhibitors: Overview
CD47 (also known as the integrin-associated signal transducer) is a cell surface molecule in the immunoglobulin superfamily that has been reported to bind to several different proteins, including integrins, thrombospondin-1, and most importantly, signal regulatory protein α (SIRPα), which is a heavily glycosylated transmembrane protein with an immunoreceptor tyrosine-based inhibition motif (ITIM). CD47 occurs in all cells, including platelets. It is an unusual member of the Ig superfamily with a V-like extracellular domain, five membrane-spanning domains, and a short cytoplasmic domain. CD47 inhibition leads to stimulation of phagocytosis of cancer cells by macrophages. Anti-CD47 antibodies enhance the phagocytosis of tumor cells by macrophages by directly blocking the binding of tumor cell-expressing CD47 to macrophage-expressing SIRPα.
• The companies and academics are working to assess challenges and seek opportunities that could influence CD47 antigen inhibitors R&D. The therapies under development are focused on novel approaches for CD47 antigen inhibitors.
CD47 antigen inhibitors Emerging Drugs Chapters
This segment of the CD47 antigen inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
CD47 antigen inhibitors Emerging Drugs
• Magrolimab: Forty Seven, Inc.
Magrolimab is a monoclonal antibody against CD47 that is designed to interfere with recognition of CD47 by the SIRPα receptor on macrophages, thus blocking the ""don't eat me"" signal used by cancer cells to avoid being ingested by macrophages. Forty Seven is initially developing magrolimab, an investigational medicine, for the treatment of patients with MDS, AML, non-Hodgkin’s lymphoma, ovarian cancer and colorectal carcinoma. Magrolimab has been granted Fast Track designation by the FDA for the treatment of MDS and AML, and for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, two forms of B-cell non-Hodgkin's lymphoma. Magrolimab has also been granted Orphan Drug designation by the FDA and European Medicines Agency for the treatment of AML.
• Evorpacept: ALX Oncology
Evorpacept targets CD47 to maximize phagocytosis of cancer cells and activate the adaptive immune system. Evorpacept enhances checkpoint inhibition by activating dendritic cells and reducing suppression by tumour-associated macrophages, and enhances targeted anti-cancer antibodies by maximising phagocytosis to selectively eliminate tumour cells. Currently, it is in Phase II stage of clinical trial evaluation to treat Squamous cell cancer.
Further product details are provided in the report……..
CD47 antigen inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different CD47 antigen inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on CD47 antigen inhibitors
There are approx. 28+ key companies which are developing the CD47 antigen inhibitors. The companies which have their CD47 antigen inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Forty Seven, Inc.
DelveInsight’s report covers around 28+ products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
CD47 antigen inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Small molecule
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
CD47 antigen inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses CD47 antigen inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CD47 antigen inhibitors drugs.
CD47 antigen inhibitors Report Insights
• CD47 antigen inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
CD47 antigen inhibitors Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs
Current Scenario and Emerging Therapies:
• How many companies are developing CD47 antigen inhibitors drugs?
• How many CD47 antigen inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of CD47 antigen inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the CD47 antigen inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for CD47 antigen inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?
• Forty Seven, Inc.
• ALX Oncology
• Shattuck Labs
• Waterstone Hanxbio
• Akeso Biopharma
• Trillium Therapeutics Inc.
• Arch Oncology
• ImmuneOncia Therapeutics
• Celgene Corporation
• ImmuneOnco Biopharma
• Light Chain Bioscience
• Trillium Therapeutics Inc
• TG Therapeutics
• MORPHIEX BIOTHERAPEUTICS
• KAHR Medical
• I-MAb Biopharma
• Centessa Pharmaceuticals
• Hanmi Pharm.Co.,Ltd.
• Innovent Biologics
• OSE Immunotherapeutics
• ZAI LAB
• EMulate Therapeutics
• Alector, Inc.
• Sorrento Therapeutics
• Surface Oncology
• QLSF Biotherapeutics
• Ichnos Sciences
• SL 172154
• HX 009
• AK 117
• TTI 622
• ISB 1442
• SAFE CD47 NEObody
• AO 176
• IMC 002
• CC 90002
• IMM 2505
• BI 765063
• IMM 0306
• NI 1801
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook